Binding-to-release (BTR) strategy enables target engagement to trigger payload release, demonstrated with 15 optimized PhoPEx compounds for improved tumor drug exposure.
Cancer Research
American Association for Cancer Research · Oncology · ISSN 0008-5472, 1538-7445
- Impact (2-yr)
- 0.6
- h-index
- 469
- Open access
- 7%
- Works
- 159.5K
- Papers this month
- 71
Track Cancer Res in JClubFree on iPhone and Android · in the app, the list is My Journals
Rebuilt
Latest in Cancer Res
Newest first · last 60 days
Spatial transcriptomics reveals that Black African American PDAC tumors have a higher prevalence of intermediate/hybrid molecular subtypes and distinct immune microenvironments compared to Non-African American tumors.
Recurrent macroscopic mechanical stress causes nuclear envelope rupture in melanoma cells and increases LRRC15-positive myofibroblasts in mouse models.
SDC4 and PKD2 mechanosensors collaboratively promote DNA damage repair in hepatocellular carcinoma by mediating matrix stiffness effects.
Parallel 4-1BB signaling in DLL3/CD56-targeting CAR T cells enhances persistence and antitumor activity in small cell lung cancer models.
Cystine restriction alleviates CD8+ T cell exhaustion and enhances CAR T-cell efficacy by targeting SLC7A11 in solid tumors.
Pregnancy induces tissue-resident memory-like CD8+ T cells in the mammary gland that are essential for reducing breast cancer risk in mice.
SEZ6-targeted α-particle radioimmunotherapy induces complete tumor regression in small cell lung cancer models.
KRAS mutations in colorectal cancer increase m6A modifications on CD73 mRNA, promoting immune evasion and tumor growth.
Serine starvation causes significant changes in mRNA splicing by reducing translation of SRSF6 in serine-auxotrophic cancer cells.
Disruption of an intragenic super-enhancer by ETV6 rearrangements downregulates CDKN1B, activating NF-κB and promoting treatment resistance in ALL.
Local activation of virus-specific memory T cells can eliminate tumors without direct tumor-cell recognition, involving inflammatory responses and immune cell recruitment.
Regression-associated macrophages promote NK cell recruitment via CCR2/5 signaling, constraining targeted therapy resistance in melanoma models.
Elevated TFAM expression in dendritic cells is linked to poor response to neoadjuvant immunochemotherapy in residual ESCC.
ARID1A upregulation in intrahepatic cholangiocarcinoma sustains Notch signaling and promotes tumor progression through TLL1 activation.
SMARCAL1 and MRN complex are key modulators of WRN dependency in MSI-H colorectal cancer cells, influencing resistance to WRN-targeted therapy.
Ligand-blocking and agonist α-TNFR2 antibodies induce tumor rejection through distinct immune mechanisms in mouse models.
Atebimetinib, a dual-MEK inhibitor, demonstrates broad activity in RAS- and RAF-mutant tumors through deep cyclic inhibition, resisting CRAF bypass and showing improved efficacy.
Atebimetinib, a novel short-half-life MEK inhibitor, outperforms binimetinib in RAS- and BRAF-mutant tumor models by enabling deep cyclic inhibition.
Schwann cells and CD4+ T cells interact to promote perineural invasion in colorectal cancer through MAPK and JAK-STAT pathway activation.
CDState accurately deconvolves malignant cell states from bulk RNA-seq data, outperforming existing methods across five cancer types with 33 TCGA datasets.
Loss of ARID2 reprograms the kynurenine-AhR pathway to restore antitumor immunity in CTNNB1-mutant hepatocellular carcinoma.
ACKR3 acts as a squamous-enriched immune checkpoint regulator that restrains tumor growth and modulates immune microenvironment in lung squamous cell carcinoma.
Inherited ccRCC risk variant rs234043 represses LINC02068, leading to mitochondrial oxidative phosphorylation attenuation and tumor progression.
A murine glioma model with patient-specific mutations closely mimics human glioblastoma’s molecular, immunologic, and functional features, including resistance to immune therapies.
KAT5 overexpression in endometrial cancer is linked to poor patient outcomes and its inhibition suppresses tumor growth and enhances immune responses.
INSR overexpression in CAR-NK and CAR-T cells stabilizes lipid rafts and maintains CAR expression, enhancing antitumor activity in gastrointestinal tumor models.
ANXA1 enhances ER-mitochondria calcium coupling by promoting contact sites, supporting lenvatinib resistance in hepatocellular carcinoma.
Overexpression of SGLT2 in CAR-T cells enhances glycolysis, mitochondrial fitness, and antitumor activity against solid tumors by increasing glucose and NaCl uptake.
Glutathione metabolism regulated by NRF2 promotes immune evasion and metastasis in breast cancer liver metastases, despite a highly immune-infiltrated microenvironment.
Track Cancer Res in JClub
Browse JClub
Journals this month
- bioRxiv6244
- medRxiv1789
- PNAS447
- Sci Adv354
- JAMA268
- Environ Res246
- BMJ196
- Nat Commun173
- Environ Pollution167
- Nature151
- Applied & Environ Microbio145
- Science141
- Lancet128
- Cell Rep127
- NEJM119
- Plant Cell Environ118
- J Exp Bot107
- mBio107
Topics moving, week to 22 Oct 2026
- Single-cell and spatial transcriptomics6
- Neuroinflammation and Neurodegeneration Mechanisms5
- Cancer Immunotherapy and Biomarkers5
- Gut microbiota and health5
- Cancer Genomics and Diagnostics4
- Bacteriophages and microbial interactions4
- CAR-T cell therapy research3
- Lung Cancer Treatments and Mutations3
- Liver Disease Diagnosis and Treatment3
- Dementia and Cognitive Impairment Research3